Quest Diagnostics has agreed to acquire some laboratory services assets from New York City-based NewYork-Presbyterian.
The assets do not include NewYork-Presbyterian's hospital-based labs. The deal is expected to be completed in the second quarter of 2023, pending regulatory approval. Terms were not disclosed.
"NewYork-Presbyterian and Quest share a belief that exceptional patient care should be accessible to all," said NewYork-Presbyterian President and CEO Steven Corwin, MD, said in a Feb. 14 Quest news release. "We determined that working with Quest would be the best path — allowing our patients wider access to advanced, quality laboratory services."